[go: up one dir, main page]

MX2012003558A - Procedimiento para la purificacion de eritropoyetina humana recombinante (epo), epo asi purificada y composiciones farmaceuticas que la comprenden. - Google Patents

Procedimiento para la purificacion de eritropoyetina humana recombinante (epo), epo asi purificada y composiciones farmaceuticas que la comprenden.

Info

Publication number
MX2012003558A
MX2012003558A MX2012003558A MX2012003558A MX2012003558A MX 2012003558 A MX2012003558 A MX 2012003558A MX 2012003558 A MX2012003558 A MX 2012003558A MX 2012003558 A MX2012003558 A MX 2012003558A MX 2012003558 A MX2012003558 A MX 2012003558A
Authority
MX
Mexico
Prior art keywords
epo
recombinant human
purified
purification
pharmaceutical compositions
Prior art date
Application number
MX2012003558A
Other languages
English (en)
Inventor
Walter Hinderer
Stefan Arnold
Original Assignee
Biogenerix Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogenerix Ag filed Critical Biogenerix Ag
Publication of MX2012003558A publication Critical patent/MX2012003558A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/505—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Se proporciona un procedimiento para la producción de eritropoyetina (EPO), en particular EPO humana recombinante (rhEPO) con una composición definida de glicoformas en una forma altamente pura, es decir, con una alta cantidad de isoformas de EPO O-glicosiladas.
MX2012003558A 2009-09-23 2010-09-23 Procedimiento para la purificacion de eritropoyetina humana recombinante (epo), epo asi purificada y composiciones farmaceuticas que la comprenden. MX2012003558A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09012120 2009-09-23
PCT/EP2010/005839 WO2011035914A1 (en) 2009-09-23 2010-09-23 Process for the purification of recombinant human erythropoietin (epo), epo thus purified and pharmaceutical compositions comprising same

Publications (1)

Publication Number Publication Date
MX2012003558A true MX2012003558A (es) 2012-07-03

Family

ID=41566362

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012003558A MX2012003558A (es) 2009-09-23 2010-09-23 Procedimiento para la purificacion de eritropoyetina humana recombinante (epo), epo asi purificada y composiciones farmaceuticas que la comprenden.

Country Status (14)

Country Link
US (1) US20120264688A1 (es)
EP (1) EP2480569B1 (es)
JP (1) JP5728016B2 (es)
KR (1) KR20120117728A (es)
CN (1) CN102712688B (es)
AU (1) AU2010297530B2 (es)
BR (1) BR112012006602A2 (es)
CA (1) CA2775012A1 (es)
EA (1) EA022396B1 (es)
IL (1) IL218721A0 (es)
MX (1) MX2012003558A (es)
UA (1) UA107678C2 (es)
WO (1) WO2011035914A1 (es)
ZA (1) ZA201202491B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101443257B1 (ko) * 2011-10-18 2014-09-19 주식회사 종근당 낮은 등전점을 갖는 에리스로포이에틴 유사체의 정제방법
US10066001B2 (en) * 2013-03-15 2018-09-04 Apotex Inc. Enhanced liquid formulation stability of erythropoietin alpha through purification processing
WO2014204023A1 (ko) * 2013-06-17 2014-12-24 씨제이헬스케어 주식회사 신규한 다베포에틴 알파의 정제 방법
US11066678B2 (en) 2013-07-18 2021-07-20 Children's Hospital Medical Center Methods of improving titer in transfection-based production systems using eukaryotic cells
US10078081B2 (en) 2014-03-05 2018-09-18 GlycoScientific LLC Isotopically labeled glycans and methods for producing the same
EP3428284B1 (en) * 2016-03-09 2022-05-11 JCR Pharmaceuticals CO., LTD. Method for producing mutant human erythropoietin
WO2017169978A1 (ja) * 2016-03-31 2017-10-05 株式会社カネカ 精製されたネコ由来エリスロポエチンの製造方法
WO2019005645A1 (en) 2017-06-26 2019-01-03 Michael Foods, Inc. YELLOW EGG FRACTIONATION
DK3613486T3 (da) * 2018-08-24 2021-01-04 Uga Biopharma Gmbh Metode og anlæg til rengøring af epo og/eller et epo-derivat
US20230009990A1 (en) * 2021-07-06 2023-01-12 Waters Technologies Corporation USE OF NEUTRAL pH MOBILE PHASES IN REVERSED PHASE CHROMATOGRAPHY OF ACIDIC PEPTIDES
CN115015415B (zh) * 2022-05-30 2025-08-01 科兴生物制药股份有限公司 重组人促红细胞生成素的含量检测方法
CN119371491B (zh) * 2024-12-25 2025-04-08 杭州诺泰诺和生物医药科技有限公司 Pegcetacoplan的纯化方法和制备方法

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ210501A (en) 1983-12-13 1991-08-27 Kirin Amgen Inc Erythropoietin produced by procaryotic or eucaryotic expression of an exogenous dna sequence
IL77081A (en) 1984-12-04 1999-10-28 Genetics Inst Dna sequence encoding human erythropoietin process for the preparation thereof and a pharmaceutical composition of human erythropoietin
US4677195A (en) 1985-01-11 1987-06-30 Genetics Institute, Inc. Method for the purification of erythropoietin and erythropoietin compositions
IL79176A (en) 1985-06-20 1992-06-21 Kirin Amgen Inc Process for the recovery of erythropoietin from a fluid
US4667016A (en) 1985-06-20 1987-05-19 Kirin-Amgen, Inc. Erythropoietin purification
EP0248656B1 (en) 1986-06-04 1993-03-31 Director-General of the Agency of Industrial Science and Technology Composition for cell cultivation and use thereof
JP2520681B2 (ja) 1986-08-04 1996-07-31 ザ ユニバーシティ オブ ニュー サウス ウェールズ 生合成のヒトの成長ホルモン製品
US4954437A (en) 1986-09-15 1990-09-04 Integrated Genetics, Inc. Cell encoding recombinant human erythropoietin
IL87737A (en) 1987-09-11 1993-08-18 Genentech Inc Method for culturing polypeptide factor dependent vertebrate recombinant cells
DE68917642T2 (de) 1988-05-25 1995-02-09 Teijin Ltd Verfahren zur kontinuierlichen Züchtung von haftenden tierischen Zellen.
KR100221066B1 (ko) 1989-10-13 1999-10-01 스튜어트 엘.왓트 에리트로포이에틴 유사체와 그를 포함하는 제약학적 조성물
US5856298A (en) * 1989-10-13 1999-01-05 Amgen Inc. Erythropoietin isoforms
EP0779362B2 (en) 1989-12-22 2012-06-13 Laboratoires Serono SA DNA constructs for endogenous gene activation and expression modification
GB9022545D0 (en) 1990-10-17 1990-11-28 Wellcome Found Culture medium
DE4115722A1 (de) 1991-05-14 1992-11-19 Boehringer Mannheim Gmbh Serumfreies medium zur kultivierung von saeugerzellen
NZ245015A (en) 1991-11-05 1995-12-21 Transkaryotic Therapies Inc Delivery of human growth hormone through the administration of transfected cell lines encoding human growth hormone, which are physically protected from host immune response; the transfected cells and their production
IL118201A (en) 1995-05-11 2004-12-15 Roche Diagnostics Gmbh Preparation comprising a protein with human erythropoietin activity which is free of serum and non-recombinant mammalian protein and process for the preparation thereof
ES2523599T3 (es) * 1997-12-03 2014-11-27 Roche Diagnostics Gmbh Eritropoyetina de gran actividad específica
BR9917606A (pt) * 1998-11-06 2002-12-31 Bio Sidus S A Procedimento para a purificação de eritropoetina humana recombinante a partir de sobrenadantes de cultivo de células e eritropoetina humana recombinante obtida com tal procedimento
CZ299516B6 (cs) * 1999-07-02 2008-08-20 F. Hoffmann-La Roche Ag Konjugát erythropoetinového glykoproteinu, zpusobjeho výroby a použití a farmaceutická kompozice sjeho obsahem
PT1311285E (pt) * 2000-05-15 2005-06-30 Hoffmann La Roche Composicao farmaceutica liquida contendo um derivado de eritropoietina
US20020045192A1 (en) * 2001-09-19 2002-04-18 St. Jude Children's Research Hospital Arf and HDM2 interaction domains and methods of use thereof
US6930086B2 (en) * 2001-09-25 2005-08-16 Hoffmann-La Roche Inc. Diglycosylated erythropoietin
PL368755A1 (en) * 2001-11-28 2005-04-04 Sandoz Ag Chromatographic purification of recombinant human erythropoietin
JP4109204B2 (ja) * 2002-03-26 2008-07-02 レツク・フアーマシユーテイカルズ・デー・デー 所望エリスロポエチングリコアイソフォームプロフィールの製造方法
DK1428878T3 (da) 2002-12-13 2008-12-08 Bioceuticals Arzneimittel Ag Fremgangsmåde til produktion og oprensning af erythropoietin
EP1537876A1 (en) 2003-12-01 2005-06-08 BioGeneriX AG Erythropoietin solution formulation
CA2551916C (en) * 2003-12-31 2014-04-29 Merck Patent Gesellschaft Mit Beschraenkter Haftung Fc-erythropoietin fusion protein with improved pharmacokinetics
CA2595676A1 (en) * 2005-01-25 2006-08-03 Apollo Life Sciences Limited Molecules and chimeric molecules thereof
JP2010509327A (ja) * 2006-11-09 2010-03-25 シナジェバ・バイオファーマ・コーポレイション トリ由来エリスロポエチン
US20090105462A1 (en) * 2006-11-09 2009-04-23 Ivarie Robert D Glycosylated erythropoietin
NZ592250A (en) * 2008-09-26 2012-11-30 Lilly Co Eli Modified animal erythropoietin polypeptides and their uses

Also Published As

Publication number Publication date
JP2013505276A (ja) 2013-02-14
US20120264688A1 (en) 2012-10-18
BR112012006602A2 (pt) 2019-09-24
CN102712688B (zh) 2015-06-24
UA107678C2 (uk) 2015-02-10
KR20120117728A (ko) 2012-10-24
AU2010297530A1 (en) 2012-04-26
EP2480569B1 (en) 2016-04-13
EP2480569A1 (en) 2012-08-01
IL218721A0 (en) 2012-06-28
WO2011035914A1 (en) 2011-03-31
ZA201202491B (en) 2012-12-27
EA201290135A1 (ru) 2012-10-30
EA022396B1 (ru) 2015-12-30
CN102712688A (zh) 2012-10-03
CA2775012A1 (en) 2011-03-31
AU2010297530B2 (en) 2013-12-19
JP5728016B2 (ja) 2015-06-03

Similar Documents

Publication Publication Date Title
MX2012003558A (es) Procedimiento para la purificacion de eritropoyetina humana recombinante (epo), epo asi purificada y composiciones farmaceuticas que la comprenden.
NZ733366A (en) Purification of iduronate-2-sulfatase
NZ600709A (en) Factor viii-fc chimeric and hybrid polypeptides, and methods of use thereof
UA102065C2 (en) Substituted 4-aryl-1,4-dihydro-1,6-naphthyridinamides and use thereof
TN2011000370A1 (en) Alkylamine-substituted dicyanopyridine and amino acid ester prodrugs thereof
MX2011007583A (es) Nuevas formulaciones estables de proteina de fusion recombinante de albumina humana-factor humano de estimulacion de colonias de granulocitos.
MX368790B (es) Factores de crecimiento de fibroblasto quimericos con especificidad de receptor alterada.
MY148258A (en) Phenylamino-benzoxazole substituted carboxylic acids, method for their production and use thereof as medicaments
BR112012015576A2 (pt) "cerâmica de vidro de dissilicato de lítio, método para sua fabricação e seu uso"
WO2006048242A3 (en) Use of pirlindole for the treatment of diseases which are characterized by proliferation of t-lymphocytes and/or hyperproliferation of keratinocytes in particular atopic dermatitis and psoriasis
UA104031C2 (uk) Диференціація мезенхімальних стовбурових клітин
MX2011009369A (es) 2-mercaptoquinolin-3-carboxamidas sustituidas como moduladores de kcnq2/3.
MY151413A (en) Compositions of prokaryotic phenylalanine ammonia-lyase and methods of using said compositions
IN2014CN03937A (es)
BR112012033404A2 (pt) polipetídeo tendo ou auxiliando a atividade de degradação de material de carboidratos e uso dos mesmos.
PH12013500820B1 (en) Method for purifying human granulocyte-colony stimulating factor from recombinant e. coli
MY155564A (en) Arginine salts and their uses for the treatment of illnesses in the oral cavity
AU2016219650A1 (en) Compositions and methods for extended therapy with aminopyridines
MX2010002557A (es) Interferon alfa 2b modificado por glicol de polietileno, la preparacion y el uso del mismo.
MX2011008825A (es) 3-aminoisoxazolopiridinas sustituidas como moduladores de kcnq2/3.
PH12021551656A1 (en) Pharmaceutical delivery compositions and uses thereof
ATE443722T1 (de) Peptide und peptidderivate, ihre herstellung sowie ihre verwendung zur herstellung einer therapeutisch und/oder prophylaktisch wirksamen pharmazeutischen zusammensetzung
NZ601142A (en) Composition for improving brain function and method for improving brain function
TN2011000595A1 (en) Substituted piperidines
MX2011008662A (es) 2-mercapto-3-aminopiridinas sustituidas como moduladores de kcnq2/3.

Legal Events

Date Code Title Description
HC Change of company name or juridical status

Owner name: NERVIANO MEDICAL SCIENCES S.R.L.*

Owner name: EVONIK DEGUSSA GMBH

FA Abandonment or withdrawal